TGen and ASU researchers find drug that could reduce risk of Alzheimer's
...y have no competing financial interests. Four of the authors hold stock in sygnis
Pharma AG, a German pharmaceutical company that owns the rights to develop this drug class as a potential memory enhancer. They stated that sygnis
was not directly involved in this study, did not fund any part of it, and d...
Brain protein improves stroke symptoms in rats, even when injected after 3 days
...humans. The BMC Biology study is the first to show that G-CSF can be effective when injected this late after a stroke event.
Armin Schneider from sygnis
Bioscience AG (formerly known as Axaron Bioscience AG) in Heidelberg, Germany, and Wolf-Rüdiger Schäbitz from the Neurology department in Münster, Ger...